Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 10/20 | 0.53 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17189237 | 0.83 | SLC5A2 (0.51) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL14278454 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1CYP2A6ADRB2IDH1 | |
| SCHEMBL28954986 | 0.82 | CYP2A6 (0.50) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL28528398 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL155503 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL19188793 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL15681536 | 0.82 | SLC5A2 (0.50) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL18197565 | 0.80 | SLC5A2 (0.48) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL28201450 | 0.79 | CYP2A6 (0.50) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL16018613 | 0.79 | CYP2A6 (0.47) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4249462-A1 | METHOD FOR PRODUCING KETONE DERIVATIVE | Tokuyama Corporation (JP) | 2023-09-27 | — | — | EP | disclosed |
| WO-2020129899-A1 | METHOD FOR PRODUCING C-ARYL HYDROXY GLYCOXIDE DERIVATIVES | 株式会社トクヤマ | 2020-06-25 | — | — | WO | disclosed |
| WO-2020129901-A1 | METHOD FOR PREPARING KETONE COMPOUND | 株式会社トクヤマ | 2020-06-25 | — | — | WO | disclosed |
| EP-3246324-A2 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USES THEREOF | Tianjin Institute Of Pharmaceutical Research (CN) | 2017-11-22 | — | — | EP | disclosed |
| EP-2776449-B1 | PROCESS FOR THE PREPARATION OF BETA-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN LTD (TW) | 2017-08-02 | — | — | EP | disclosed |
| US-20170057989-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2017-03-02 | — | — | US | disclosed |
| US-9505734-B2 | Phenyl C-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2016-11-29 | — | — | US | disclosed |
| WO-2016098016-A1 | PROCESS FOR THE PREPARATION OF SGLT2 INHIBITORS | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-06-23 | — | — | WO | disclosed |
| EP-2933250-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | Tianjin Institute Of Pharmaceutical Research (CN) | 2015-10-21 | — | — | EP | disclosed |
| US-8952139-B2 | Process for the preparation of β-C-aryl glucosides | SCINOPHARM TAIWAN, LTD (TW) | 2015-02-10 | — | — | US | disclosed |
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SCINOPHARM TAIWAN, LTD. (TW) | 2014-05-08 | — | — | US | disclosed |
| WO-2013068850-A2 | PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN, LTD. (NA) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885CHRM1 4790/4885 |
| US-20170057989-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | GCG, SLC5A1, DPP7 | SLC5A2 6/4885SLC5A1 2/4885CHRM1 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.